SI
AGIO icon

Sofinnova Investments’s Agios Pharmaceuticals AGIO Stock Holding History

Sofinnova Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-219,033
Closed -$12.1M – 72
2021
Q2 		$12.1M Buy
+219,033
New +$12.2M 0.7% 36

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Sofinnova Investments's AGIO Position: Q3 2021 in Review

Sofinnova Investments sold out of Agios Pharmaceuticals (AGIO) in Q3 2021, closing a stake of 219,033 shares — an estimated $12.1M sold.

Sofinnova Investments first reported a position in AGIO in Q2 2021 and held it in 1 quarter. The position peaked at $12.1M in Q2 2021. 164 funds tracked by Wall St. Rank hold AGIO as of Q3 2021.

  • Sofinnova Investments reported no remaining Agios Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sofinnova Investments sold 219,033 Agios Pharmaceuticals shares in Q3 2021, an estimated $12.1M.
  • Sofinnova Investments first reported a position in Agios Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Sofinnova Investments's Agios Pharmaceuticals position peaked at $12.1M in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2021.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.